Top ▲

KIR3DL2 (CD158K)

Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 3067

Nomenclature: KIR3DL2 (CD158K)

Family: CD molecules

Annotation status:  image of a red circle Awaiting annotation  » Email us

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 455 19q13.42 KIR3DL2 killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2
Mouse 1 409 Chromosome X, 58.77 cM Kir3dl1 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1
Gene and Protein Information Comments
Alternatively spliced transcript variants that encode different protein isoforms have been identified for human KIR3DL2 [1] and its mouse ortholog Kir3dl1.
Previous and Unofficial Names Click here for help
killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 | killer cell immunoglobulin-like receptor | cl-5 | Kirl1 (Mm) | nkat4 | nkat4a
Database Links Click here for help
Alphafold
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
lacutamab Peptide Immunopharmacology Ligand Hs Binding >9.0 pKd 2
⤷ pKd >9.0 (Kd <1x10-9 M) [2]
Immunopharmacology Comments
KIR3DL2 mediates NK cell coinhibitory signals when it binds to MHC class I molecules on other cells. Binding to HLA-A3 , HLA-A11 [3] and HLA-B27 [4] has been reported, as has binding to CpG oligodeoxynucleotides [7].

KIR3DL2 is highly expressed on the malignant cells in cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome, and has been reported to promote resistance to NK cell-induced cell death in some CTCLs [8]. Blockade of the suppressive signal mediated by KIR3DL2 using a monoclonal antibody (Innate Pharma's IPH4102) is being investigated as a therapeutic approach for the treatment of T cell lymphomas such as Sézary syndrome [5-6,9].
Immuno Process Associations
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 1 GO processes
GO:0002767 immune response-inhibiting cell surface receptor signaling pathway IBA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 1 GO processes
GO:0002767 immune response-inhibiting cell surface receptor signaling pathway IBA
General Comments
KIR3DL2 is one of a family of 18 human genes that encode MHC class I receptors on the surface of nautral killer (NK) cells and some cytotoxic T cell subsets (HGNC gene group link: Killer cell immunoglobulin like receptors (KIR)). Most KIR proteins mediate inhibitory signals that suppress the cytotoxic activity of the NK cell on which they are expressed. KIR3DL2 is an immuno-oncology therapeutic target.

References

Show »

1. Döhring C, Samaridis J, Colonna M. (1996) Alternatively spliced forms of human killer inhibitory receptors. Immunogenetics, 44 (3): 227-30. [PMID:8662091]

2. Gauthier L, Schneider N. (2019) Humanized antibodies with increased stability. Patent number: US10280222B2. Assignee: Innate Pharma SA. Priority date: 12/03/2015. Publication date: 07/05/2019.

3. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H, Rowland-Jones S, Braud VM. (2004) Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol, 34 (6): 1673-9. [PMID:15162437]

4. Kollnberger S, Chan A, Sun MY, Chen LY, Wright C, di Gleria K, McMichael A, Bowness P. (2007) Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur J Immunol, 37 (5): 1313-22. [PMID:17407096]

5. Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, Bonnafous C, Rossi B, Bléry M, Paturel C et al.. (2014) IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res, 74 (21): 6060-70. [PMID:25361998]

6. Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A. (2015) A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. Oncoimmunology, 4 (9): e1022306. [PMID:26405593]

7. Sivori S, Falco M, Carlomagno S, Romeo E, Soldani C, Bensussan A, Viola A, Moretta L, Moretta A. (2010) A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood, 116 (10): 1637-47. DOI: 10.1182/blood-2009-12-256586 [PMID:20147700]

8. Thonnart N, Caudron A, Legaz I, Bagot M, Bensussan A, Marie-Cardine A. (2014) KIR3DL2 is a coinhibitory receptor on Sézary syndrome malignant T cells that promotes resistance to activation-induced cell death. Blood, 124 (22): 3330-2. DOI: 10.1182/blood-2014-09-598995 [PMID:25414436]

9. Van Der Weyden C, Bagot M, Neeson P, Darcy PK, Prince HM. (2018) IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs, 27 (8): 691-697. [PMID:30001170]

How to cite this target page

CD molecules: KIR3DL2 (CD158K). Last modified on 11/08/2026. Accessed on 17/11/2026. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=3067.